| Hans-Günter Meyer-Thompson | Hepatitiden
Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
Merat SJ, Bru C, van de Berg D, Molenkamp R, Tarr AW, Koekkoek S, Kootstra NA, Prins M, Ball JK, Bakker AQ, de Jong MD, Spits H, Beaumont T, Schinkel J.
J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30128-X. doi: 10.1016/j.jhep.2019.02.013.
https://www.journal-of-hepatology.eu/article/S0168-8278(19)30128-X/fulltext